According to a 2024 memo issued by the Centers for Medicare and Medicaid Services (CMS), reducing cardiovascular risk is considered a medically accepted indication, so individuals taking Wegovy for this specific reason may be able to receive coverage through Medicare Part D
But this is usually an effect that is quickly felt
In a recent regulatory shift, the FDA has ended the allowance for compounding pharmacies to produce copycat versions of popular GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
By having more stable glucose levels, they reduce the hormonal spikes and support metabolic health
Glutathione provides antioxidant support, while collagen helps maintain skin elasticity and structure
doi: 10.1107/S0907444912001308 3 Ayoub MoubareckC.Hammoudi HalatD